PMC:7600245 / 29207-29541
Annnotations
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T108 | 71-79 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T109 | 275-284 | Disease | denotes | influenza | http://purl.obolibrary.org/obo/MONDO_0005812 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T268 | 104-106 | http://purl.obolibrary.org/obo/CLO_0001000 | denotes | 35 |
| T269 | 200-201 | http://purl.obolibrary.org/obo/CLO_0001021 | denotes | b |
| T270 | 285-290 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T409 | 11-30 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
| T410 | 11-20 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
| T411 | 21-30 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
| T412 | 158-176 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
| T413 | 186-189 | Chemical | denotes | INF | http://purl.obolibrary.org/obo/CHEBI_52999 |
| T414 | 193-196 | Chemical | denotes | INF | http://purl.obolibrary.org/obo/CHEBI_52999 |
| T415 | 206-224 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
| T416 | 229-240 | Chemical | denotes | oseltamivir | http://purl.obolibrary.org/obo/CHEBI_7798 |
| T417 | 245-254 | Chemical | denotes | inhibitor | http://purl.obolibrary.org/obo/CHEBI_35222 |
LitCovid-PD-GO-BP
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T50 | 141-152 | http://purl.obolibrary.org/obo/GO_0000746 | denotes | conjugation |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T216 | 0-334 | Sentence | denotes | Currently, lopinavir/ritonavir is being evaluated for the treatment of SARS-CoV-2 patients in more than 35 interventional trials alone or in conjugation with hydroxychloroquine, inhaled INF-α, INF-β 1b and hydroxychloroquine, or oseltamivir (an inhibitor of neuraminidase in influenza virus) (for details refer to clinicaltrials.gov). |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 812 | 186-191 | Gene | denotes | INF-α | Gene:3451 |
| 813 | 258-271 | Gene | denotes | neuraminidase | Gene:4758 |
| 815 | 71-81 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
| 816 | 82-90 | Species | denotes | patients | Tax:9606 |
| 817 | 275-290 | Species | denotes | influenza virus | Tax:11308 |
| 823 | 11-30 | Chemical | denotes | lopinavir/ritonavir | MESH:C558899 |
| 824 | 158-176 | Chemical | denotes | hydroxychloroquine | MESH:D006886 |
| 825 | 229-240 | Chemical | denotes | oseltamivir | MESH:D053139 |